Adaptive Biotechnologies' clonoSEQ Named in Updated NCCN Guidelines for Multiple Myeloma
Adaptive Biotechnologies (NASDAQ:ADPT) announced that its clonoSEQ test was included in updated National Comprehensive Cancer Network (NCCN) guidelines for multiple myeloma. The new recommendations expand the use of MRD monitoring to include annual assessments during maintenance and after later treatment lines, potentially increasing testing frequency per patient. The company has already seen strong commercial growth, with a 43% year-over-year increase in clonoSEQ test volume and $66.2 million in MRD business revenue for Q2 2026. Management raised its full-year guidance to between $268 million and $278 million. While Medicare already covers the test, broader adoption depends on clinician behavior, patient compliance, and payer reimbursement policies across different insurance plans.
Tickers: $ADPT
Topics: clonoSEQ MRD testing multiple myeloma NCCN guidelines